![](img037.GIF) |
Evidence-based guidelines for the management of
individuals with Factor V Leiden mutations are not yet available. Therefore,
it is recommended that benefits and risks of various clinical options be
discussed with patients, and their preferences considered in genetic testing
decisions.
Most individuals did not have adequate knowledge about Factor V Leiden
mutations. Possible improvements include obtaining written consent for
genetic testing, better communication with patients to confer genetic test
results, evaluation of healthcare provider training about Factor V Leiden,
and better tools for educating patients, including specialized thrombosis
clinics, printed material and internet-based programs. |